These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 24922307)

  • 1. Pharmacogenomics of human uridine diphospho-glucuronosyltransferases and clinical implications.
    Guillemette C; Lévesque É; Rouleau M
    Clin Pharmacol Ther; 2014 Sep; 96(3):324-39. PubMed ID: 24922307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. UGT genomic diversity: beyond gene duplication.
    Guillemette C; Lévesque E; Harvey M; Bellemare J; Menard V
    Drug Metab Rev; 2010 Feb; 42(1):24-44. PubMed ID: 19857043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. UGT pharmacogenomics: implications for cancer risk and cancer therapeutics.
    Desai AA; Innocenti F; Ratain MJ
    Pharmacogenetics; 2003 Aug; 13(8):517-23. PubMed ID: 12893990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucuronidation and the UDP-glucuronosyltransferases in health and disease.
    Wells PG; Mackenzie PI; Chowdhury JR; Guillemette C; Gregory PA; Ishii Y; Hansen AJ; Kessler FK; Kim PM; Chowdhury NR; Ritter JK
    Drug Metab Dispos; 2004 Mar; 32(3):281-90. PubMed ID: 14977861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer.
    Nagar S; Remmel RP
    Oncogene; 2006 Mar; 25(11):1659-72. PubMed ID: 16550166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenomics of human UDP-glucuronosyltransferase enzymes.
    Guillemette C
    Pharmacogenomics J; 2003; 3(3):136-58. PubMed ID: 12815363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. UDP-glucuronosyltransferases and clinical drug-drug interactions.
    Kiang TK; Ensom MH; Chang TK
    Pharmacol Ther; 2005 Apr; 106(1):97-132. PubMed ID: 15781124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gender-dependent differences in uridine 5'-diphospho-glucuronosyltransferase have implications in metabolism and clearance of xenobiotics.
    Liu W; Kulkarni K; Hu M
    Expert Opin Drug Metab Toxicol; 2013 Dec; 9(12):1555-69. PubMed ID: 24011176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Species differences in drug glucuronidation: Humanized UDP-glucuronosyltransferase 1 mice and their application for predicting drug glucuronidation and drug-induced toxicity in humans.
    Fujiwara R; Yoda E; Tukey RH
    Drug Metab Pharmacokinet; 2018 Feb; 33(1):9-16. PubMed ID: 29079228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro metabolism of canagliflozin in human liver, kidney, intestine microsomes, and recombinant uridine diphosphate glucuronosyltransferases (UGT) and the effect of genetic variability of UGT enzymes on the pharmacokinetics of canagliflozin in humans.
    Francke S; Mamidi RN; Solanki B; Scheers E; Jadwin A; Favis R; Devineni D
    J Clin Pharmacol; 2015 Sep; 55(9):1061-72. PubMed ID: 25827774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review.
    Stingl JC; Bartels H; Viviani R; Lehmann ML; Brockmöller J
    Pharmacol Ther; 2014 Jan; 141(1):92-116. PubMed ID: 24076267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucuronidation in humans. Pharmacogenetic and developmental aspects.
    de Wildt SN; Kearns GL; Leeder JS; van den Anker JN
    Clin Pharmacokinet; 1999 Jun; 36(6):439-52. PubMed ID: 10427468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human variability in isoform-specific UDP-glucuronosyltransferases: markers of acute and chronic exposure, polymorphisms and uncertainty factors.
    Kasteel EEJ; Darney K; Kramer NI; Dorne JLCM; Lautz LS
    Arch Toxicol; 2020 Aug; 94(8):2637-2661. PubMed ID: 32415340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucuronidation of antiallergic drug, Tranilast: identification of human UDP-glucuronosyltransferase isoforms and effect of its phase I metabolite.
    Katoh M; Matsui T; Yokoi T
    Drug Metab Dispos; 2007 Apr; 35(4):583-9. PubMed ID: 17220234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-glucuronidation of drugs and other xenobiotics by human and animal UDP-glucuronosyltransferases.
    Kaivosaari S; Finel M; Koskinen M
    Xenobiotica; 2011 Aug; 41(8):652-69. PubMed ID: 21434773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pharmacogenetic study of vorinostat glucuronidation.
    Kang SP; Ramirez J; House L; Zhang W; Mirkov S; Liu W; Haverfield E; Ratain MJ
    Pharmacogenet Genomics; 2010 Oct; 20(10):638-41. PubMed ID: 20729791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uridine 5'-diphospho-glucronosyltrasferase: Its role in pharmacogenomics and human disease.
    Sanchez-Dominguez CN; Gallardo-Blanco HL; Salinas-Santander MA; Ortiz-Lopez R
    Exp Ther Med; 2018 Jul; 16(1):3-11. PubMed ID: 29896223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic variation of human UDP-glucuronosyltransferase: implications in disease and drug glucuronidation.
    Burchell B
    Am J Pharmacogenomics; 2003; 3(1):37-52. PubMed ID: 12562215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug metabolizing enzymes related to laboratory medicine: cytochromes P-450 and UDP-glucuronosyltransferases.
    Batt AM; Magdalou J; Vincent-Viry M; Ouzzine M; Fournel-Gigleux S; Galteau MM; Siest G
    Clin Chim Acta; 1994 May; 226(2):171-90. PubMed ID: 7923812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Family 1 uridine-5'-diphosphate glucuronosyltransferases (UGT1A): from Gilbert's syndrome to genetic organization and variability.
    Strassburg CP; Lankisch TO; Manns MP; Ehmer U
    Arch Toxicol; 2008 Jul; 82(7):415-33. PubMed ID: 18491077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.